SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Dizal to Present Clinical Data at ASH 2026

Dizal says data on golidocitinib monotherapy in adults with secondary HLH will be featured at ASH 2026. The body says the treatment showed a high and durable response.

Related stories